ADMA FDA decision — May 4, 2026
✓ APPROVED
ADMA Biologics Inc — ASCENIV (RI-002) · Primary humoral immunodeficiency (PI) to pediatric.
Run-up into the decision (T-120 → T+5) PDUFA 5/4/26 $20.38 $8.29 11/17/25 Daily close, T-120 (11/17/25) through T+5. Run-up high $20.38 on 12/18/25, low $8.29 on 3/27/26 (T-120 to T-1). FDA decision 5/4/26. Historical price action, not a forecast.
Key facts
FDA decision date 2026-05-04
Outcome Approved
Drug / candidate ASCENIV (RI-002)
Company ADMA Biologics Inc
120-day run-up (T-120→T-1) -27.5%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio